Last, we summarize understanding of the central role of the early induced innate immune response in gouty
inflammation, which has suggested the potential value of new strategies for treating gouty
inflammation by targeting caspase-1 or IL-1[beta].
They recommend that colchicine prophylaxis continue until the urate level has stabilized at the target level and the patient has not had an acute gouty
attack for 3-6 months.
Three-phase skeletal scintigraphy in gouty
arthritis: an example of potential diagnostic pitfalls in radiopharmaceutical imaging of the extremities for infection.
A diagnostic rule for acute gouty
arthritis in primary care without joint fluid analysis" (Arch.
These are individuals who, despite maximum therapy, continue to have high serum urate levels, tophi, or frequent gouty
attacks, some a combination.
Patients with a history of more than four gouty
attacks per year or with polyarticular attacks had higher serum urate during the episode studied than those without those characteristics.
While most humans have "normal" uric acid levels in the 4 to 7 mg/dL range, physicians know that many patients have serum uric acid levels that are higher, and it is these levels that tend to increase the risk for gouty
attacks, tophi, or both.
Allopurinol shouldn't be started during an acute gouty
attack and shouldn't be stopped in those already on treatment, he added.
In the NDA, Merck is seeking indications for ARCOXIA for the treatment of osteoarthritis, rheumatoid arthritis, chronic low back pain, acute pain, dysmenorrhea (menstrual pain), acute gouty
arthritis and ankylosing spondylitis.
Men with a history of gouty
arthritis have a significantly higher risk of acute myocardial infarction, reported Dr.
He was well known in London for sending his gouty
carriage-trade patients abroad to "take the waters" uncontaminated by lead.
Data from efficacy studies evaluating ARCOXIA versus naproxen in the treatment of ankylosing spondylitis and ARCOXIA versus indomethacin in the treatment of acute gouty
arthritis also are being presented at the annual meeting of the American College of Rheumatology.